期刊文献+

丙型肝炎个体化规范治疗的应答指导治疗策略的临床研究 被引量:1

下载PDF
导出
摘要 众多有关PEG—IFNα-2a干扰素治疗应答相关因素的研究结果表明,血清HCV—RNA载量和病毒基因型是患者能否取得持续性应答(SVR)的预测因子,而患者的个体差异需要进行个体化治疗。应答指导治疗(RGT)策略包括治疗因素(应答快慢、应答程度)、病毒因素(病毒基因型、病毒载量)、宿主因素(年龄、人种)。本研究探讨RGT对丙肝个体化规范治疗的影响,现报告如下。
出处 《实用临床医药杂志》 CAS 2013年第23期143-144,148,共3页 Journal of Clinical Medicine in Practice
  • 相关文献

参考文献7

  • 1Ge D, Fellay J, Thonnpson A J, et al. Genetic Variation in 1L28B predicts hepatitis c treatment induled viral elearanee [n NATURE, 2009, 461(7262): 399.
  • 2Liao Xu, Ling Y, Zhang X X, et al. Association of genetic Variation in 1L28B with the hepatitis C treatment - induced, Viral clearance in the Chinese Han population [J]. Antivir Ther, 2010, (inpress}: 123.
  • 3Ghany M G, Strader D B, Thomas D L, et al. Diagnosis, management and tream ent of hepatitiscralupdate[J]. Hepatology , 2009, 49(4): 1335.
  • 4Savino B, Mitche IlLS, Stuartk R, et al. Efficacy and safety of Peginterferon AHa - 2a( 40Kd) pius Rbavirin in Hepatitis C patients with Advanced Fibrosis and cirrhosis[J]. Hepatology, 2010, 51(2): 388.
  • 5Dong G, Jacques F, Alexander J. et al. Genetic variation in IL28B predicts hepatitis C treatment - induced viral Clearance [J]. Nature, 2009, 461: 399.
  • 6于建武,孙丽杰,李晓光,李树臣.快速和早期病毒学应答对慢性丙型肝炎患者持续病毒学应答的预测价值[J].中华传染病杂志,2008,26(1):36-39. 被引量:19
  • 7Fried M W, Hadziyannis S J, Shifilman M, et al. Rapid virologicalresponset SVR) than genotype in patients with chronic hepatitis C virur infection [J]. Hepatology, 2008, 48 (12) : 35.

二级参考文献10

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2于建武,赵勇华,李晓光,李树臣.黑龙江省慢性丙型肝炎病毒感染者的血清型及其临床意义[J].中华传染病杂志,2006,24(1):15-16. 被引量:1
  • 3Davis GL, Wong JB, McHutchison JG, et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 2003, 38: 645-652.
  • 4Reddy K, Rakela J, Lopez-Talavera J, et al. Correlation between rapid virologic response, early virologic response and sustained virologic response in HCV genotype 1 patients with pegylated interferon alfa 2a and ribavirin. Gastroenterology, 2005, 128:S1540.
  • 5Kobayashi M, Chayama K, Arase Y, et al. Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6. J Gastroenterol, 1999, 34:505-509.
  • 6Hoofnagle JH, Ghany MG, Kleiner DE, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology, 2003, 38 : 66-74.
  • 7Zeuzem S, Lee JH, Franke A, et al. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology, 1998, 27:1149-1156.
  • 8Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pre treatment viremia. J Hepatol, 2006, 44:97-103.
  • 9Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa- 2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med, 2005, 352:2609-2617.
  • 10谢尧,徐道振,陆志檬,骆抗先,贾继东,王宇明,赵桂珍,张树林,张大志.HCV基因型对慢性丙型肝炎干扰素疗效的影响[J].中华肝脏病杂志,2004,12(2):72-75. 被引量:50

共引文献18

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部